Fluorescence in Situ Hybridization Medical Services in China

Fluorescence in Situ Hybridization (FISH) is not a disease but a highly sensitive molecular cytogenetic diagnostic technique widely used in hematology to detect specific chromosomal abnormalities—including deletions, duplications, translocations, and gene amplifications—in blood, bone marrow, or lymph node specimens. In the Department of Hematology, FISH plays a pivotal role in the diagnosis, risk stratification, and therapeutic monitoring of hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), multiple myeloma (MM), myelodysplastic syndromes (MDS), and lymphomas. Unlike conventional karyotyping, FISH can identify submicroscopic aberrations in interphase nuclei—making it especially valuable when metaphase cells are scarce or culture failure occurs. Pathogenetically, FISH detects structural or numerical chromosomal alterations that drive oncogenesis: for example, the t(9;22) BCR-ABL1 fusion in chronic myeloid leukemia (CML), del(13q) and del(11q) in CLL, del(5q) in MDS, or IGH translocations in MM. These abnormalities disrupt critical regulatory genes involved in cell cycle control, apoptosis, and differentiation, leading to clonal expansion of malignant hematopoietic cells. Epidemiologically, FISH testing is routinely performed across all age groups with suspected hematologic neoplasms; its utilization correlates strongly with incidence rates of underlying conditions—e.g., CLL peaks in adults over 65 (incidence ~4–5/100,000/year), while AML incidence rises sharply after age 60 (~20/100,000 in those >80). Risk factors for requiring FISH testing are thus tied to clinical indicators—not patient lifestyle—but include unexplained cytopenias, persistent lymphocytosis, abnormal peripheral smear findings, elevated serum free light chains, or radiographic evidence of lytic bone lesions. Importantly, FISH itself carries no inherent morbidity; however, delays or inaccuracies in FISH-based diagnosis may adversely impact quality of life by postponing targeted therapy, increasing anxiety during diagnostic uncertainty, or leading to inappropriate chemotherapy regimens. Timely, precise FISH results directly influence treatment selection—such as initiating tyrosine kinase inhibitors in BCR-ABL1+ cases or considering lenalidomide in del(5q) MDS—thereby improving symptom control, transfusion independence, progression-free survival, and overall functional status. Patients benefit from reduced hospitalizations, fewer adverse drug reactions, and enhanced psychosocial well-being when FISH-guided precision management is integrated early into their care pathway.

Fluorescence in Situ Hybridization (FISH) is not a therapeutic modality but a highly sensitive, targeted molecular cytogenetic diagnostic technique widely employed in hematology to detect specific chromosomal abnormalities—including deletions, duplications, translocations, and gene amplifications—in hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), multiple myeloma (MM), myelodysplastic syndromes (MDS), and lymphomas. As a diagnostic and prognostic tool—not a treatment—FISH informs clinical decision-making across the entire therapeutic continuum. Its role is foundational in risk stratification, treatment selection, minimal residual disease (MRD) monitoring, and response assessment. Therefore, discussion of 'treatment' for FISH is inherently a discussion of how FISH-guided management optimizes conservative, pharmacologic, and procedural interventions in hematologic oncology.

Conservative treatment strategies in hematology rely heavily on FISH results to determine observation versus intervention. For example, in asymptomatic early-stage CLL with favorable FISH findings—such as isolated 13q14 deletion—watchful waiting remains standard, avoiding unnecessary cytotoxic exposure. Conversely, detection of high-risk abnormalities like del(17p) (affecting TP53) or complex karyotype by FISH mandates prompt initiation of targeted therapy. Similarly, in MDS, identification of isolated del(5q) by FISH confirms eligibility for lenalidomide monotherapy, whereas del(7q) or monosomy 7 signals higher progression risk and may prompt earlier consideration of hypomethylating agents or allogeneic hematopoietic stem cell transplantation (allo-HSCT). Thus, conservative management is not passive but precision-informed: FISH enables tailored surveillance intervals, timely blood count monitoring, and preemptive supportive care (e.g., growth factor support, iron chelation in transfusion-dependent patients) based on genomic risk.

Medication regimens are profoundly shaped by FISH outcomes. In AML, detection of core-binding factor (CBF) translocations—t(8;21) or inv(16)—confirms favorable risk and supports intensive cytarabine/anthracycline-based induction, often omitting experimental agents. In contrast, FISH-confirmed KMT2A (MLL) rearrangements in infant ALL or AML indicate poor prognosis and justify incorporation of menin inhibitors (e.g., revumenib) in clinical trials or intensified chemotherapy. For MM, FISH on purified CD138+ plasma cells identifies high-risk lesions including del(17p), t(4;14), and amp(1q), which guide triplet or quadruplet induction (e.g., daratumumab–lenalidomide–bortezomib–dexamethasone) and early consolidation with autologous HSCT. Importantly, FISH detects abnormalities missed by conventional karyotyping due to low mitotic index or poor metaphase yield—particularly critical in myeloid neoplasms where interphase FISH achieves >95% sensitivity for key targets. Therapeutic decisions thus pivot on FISH-defined biomarkers rather than morphology alone.

Surgical treatment has no direct role in FISH application; however, FISH critically informs indications for hematopoietic stem cell transplantation. Detection of adverse cytogenetics—such as del(17p) in CLL, complex karyotype in MDS, or persistent high-risk FISH abnormalities post-induction in AML—strengthens the indication for allo-HSCT in eligible patients. Pre-transplant FISH assessment ensures accurate donor selection and conditioning intensity, while post-transplant serial FISH on bone marrow aspirates monitors engraftment kinetics and early relapse. Though bone marrow biopsy and aspiration are invasive procedures, they are essential specimen sources for FISH analysis—not surgical treatments per se, but indispensable diagnostic interventions enabling definitive therapeutic planning.

China offers distinct advantages in FISH-integrated hematologic care. First, national standardization initiatives led by the Chinese Society of Hematology have established uniform FISH probe panels, validation protocols, and proficiency testing across over 300 certified centers—including tier-3 hospitals in Beijing, Shanghai, Guangzhou, and Chengdu. Second, domestic development of cost-effective, CE-IVD–certified FISH kits (e.g., by Nanjing Vazyme, Shenzhen Hybio) has reduced assay costs by ~40% compared to imported equivalents, improving accessibility in regional hospitals. Third, AI-enhanced digital FISH platforms—deployed at Peking University People’s Hospital and Ruijin Hospital—automate signal enumeration and reduce inter-observer variability, achieving >99% concordance with expert review. Fourth, China’s large patient volume facilitates rapid enrollment into FISH-stratified clinical trials (e.g., NCT04783706 evaluating zilovertamab in del(17p) CLL), accelerating evidence generation. Finally, integrated electronic health records link FISH data directly to treatment pathways in national registries (e.g., China Hematology Big Data Platform), enabling real-time outcome analytics and quality improvement.

Recovery advice following FISH-guided therapy emphasizes longitudinal genomic surveillance and holistic supportive care. Patients should undergo repeat FISH at defined intervals: post-induction and pre-consolidation in AML; every 6 months during active CLL treatment; and annually in low-risk MDS under observation. Bone marrow sampling remains the gold standard, though emerging data support peripheral blood FISH for certain markers (e.g., del(13q) in CLL) when marrow is inaccessible. Patients must be counseled on the limitations of FISH—it assesses only predefined loci and cannot replace whole-genome sequencing for novel alterations. Recovery also entails managing treatment sequelae: infection prophylaxis during BTK inhibitor therapy, neuropathy monitoring with proteasome inhibitors, and fertility preservation discussions prior to intensive regimens. Nutritional support, psychosocial counseling, and vaccination adherence (especially pneumococcal and influenza vaccines in immunocompromised hosts) are integral. Crucially, patients should maintain accessible, encrypted digital copies of their FISH reports—including probe names, signal counts, and interpretation—to facilitate continuity across institutions. Long-term survivorship programs in major Chinese centers now incorporate FISH-based risk recalibration, ensuring dynamic adaptation of surveillance and intervention as genomic landscapes evolve.